CFO
BEAM icon

CVA Family Office’s Beam Therapeutics BEAM Stock Holding History

CVA Family Office’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$721 Buy
21
+20
+2,000% +$604 ﹤0.01% 1681
2026
Q1 		$24 Buy
+1
New +$28 ﹤0.01% 1835
2025
Q2 		– Sell
-22
Closed -$430 – 1308
2025
Q1 		$430 Hold
22
– – ﹤0.01% 1352
2024
Q4 		$546 Hold
22
– – ﹤0.01% 1208
2024
Q3 		$539 Hold
22
– – ﹤0.01% 1198
2024
Q2 		$515 Buy
+22
New +$540 ﹤0.01% 1196

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

CVA Family Office's BEAM Position: Q2 2026 in Review

CVA Family Office increased its Beam Therapeutics (BEAM) stake by 2,000% in Q2 2026, buying an estimated $604 and bringing the position to 21 shares worth $721. The position accounts for ﹤0.01% of the portfolio, ranked #1681.

CVA Family Office first reported a position in BEAM in Q2 2024 and has held it in 6 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • CVA Family Office held 21 shares of Beam Therapeutics worth $721 as of Q2 2026.
  • CVA Family Office bought 20 Beam Therapeutics shares in Q2 2026, an estimated $604.
  • Beam Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1681 holding.
  • CVA Family Office first reported a position in Beam Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.